Drugs / JNJ-48816274
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02852395 | Aug 2016 → May 2018 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-48816274 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02852395 ↗ |
| Route | Oral | “Oral dose; dose range of 5 mg up to 250 mg” NCT02852395 ↗ |